sarscov
sever
acut
respiratori
syndromeassoci
coronaviru
strain
partial
purifi
inactiv
formaldehyd
cell
cultur
inactiv
viru
block
replic
live
viru
decreas
tcid
live
viru
time
inactiv
use
immun
mice
intranas
either
alon
precipit
polyethylen
glycol
peg
cpg
ctb
adjuv
titer
serum
neutral
antibodi
mice
immun
adjuv
peg
precipit
specif
iga
detect
tracheallung
wash
fluid
immunofluoresc
though
serum
antibodi
detect
antisarsiga
could
detect
mice
immun
inactiv
role
adjuv
intranas
immun
inactiv
sarscov
discuss
sar
sever
acut
respiratori
syndrom
caus
new
coronaviru
provision
term
sarsassoci
coronaviru
sarscov
etiolog
relationship
genom
sequenc
sarscov
independ
report
variou
group
indic
viru
belong
previous
defin
group
coronavirida
assign
fourth
group
coronavirida
sarscov
highli
infecti
origin
still
clearli
identifi
effect
vaccin
protect
popul
urgent
need
among
possibl
approach
develop
vaccin
sar
inactiv
sarscov
vaccin
rank
top
list
high
replic
compet
viru
cell
cultur
wellestablish
inactiv
process
coronavirus
previou
success
use
inactiv
felin
coronaviru
vaccin
prevent
diseas
date
pathogenesi
sar
yet
fulli
studi
howev
possibl
role
host
antisarscov
immun
respons
suggest
sever
clinic
case
addit
antibodymedi
enhanc
felin
coronaviru
infect
document
risk
sarscov
antibodi
enhanc
phenomenon
mediat
inactiv
vaccin
induc
antibodi
vaccin
need
serious
consid
intranas
immun
use
inactiv
sarscov
vaccin
could
effect
block
live
sarscov
site
entri
induc
antibodi
respiratori
tract
serum
besid
viru
infect
block
site
entri
may
less
risk
vaccin
develop
antibodi
enhanc
phenomenon
herein
report
experiment
immun
mice
inactiv
sarscov
mice
specif
iga
detect
tracheallung
wash
fluid
neutral
antibodi
serum
intranas
immun
mice
sarscov
strain
genbank
access
number
isol
nasopharyng
wash
fluid
femal
patient
suffer
sar
guangzhou
late
februari
strain
first
isol
use
cell
line
passag
vero
cell
inocul
viru
tcid
per
flask
greiner
labortechnik
germani
cpe
detect
earli
h
peak
h
serial
passag
strain
vero
cell
consist
yield
cpe
viru
titer
tcid
fulllength
sequenc
phylogenet
analysi
show
laid
report
hong
kong
strain
canadian
us
strain
studi
whether
share
antigen
viru
strain
citi
china
aceton
fix
cell
use
react
convalesc
sera
hong
kong
guangdong
shanghai
patient
convalesc
sera
show
similar
posit
titer
indirect
immunofluoresc
assay
data
shown
formaldehyd
sigma
concentr
c
h
complet
inactiv
crude
inactiv
viru
solut
spun
rpm
h
sucros
cushion
precipit
resuspend
pb
inactiv
viru
confirm
use
time
concentr
formaldehyd
treat
viru
viral
copi
number
ml
inocul
vero
cell
cpe
detect
cell
supernat
blindli
passag
three
passag
cell
cultur
fix
cold
aceton
stain
sar
antibodi
posit
convalesc
serum
indirect
immunofluoresc
assay
posit
stain
cell
found
inactiv
influenza
type
viru
strain
licens
vaccin
current
use
human
china
provid
without
adjuv
shanghai
institut
biolog
product
serv
neg
control
block
assay
live
sarscov
replic
studi
whether
formaldehydeinactiv
retain
bind
site
versu
cell
receptor
examin
block
effect
inactiv
sarscov
replic
live
sarscov
virus
cell
cultur
vero
cell
cultur
plate
treat
l
per
well
inactiv
viru
solut
dilut
cultur
medium
neat
concentr
viru
pool
use
copi
viral
genomeml
assay
realtim
pcr
diagnost
kit
provid
daan
co
guangzhou
well
treat
inactiv
virus
triplic
h
c
control
cell
treat
cultur
medium
one
hundr
microlit
live
ghgz
viru
copi
viral
genomeml
dilut
ad
inactiv
viru
treat
well
control
well
cpe
record
h
inocul
live
viru
h
cultur
medium
decant
treat
l
formaldehyd
min
follow
stain
coomasi
blue
h
manipul
done
hood
laboratori
block
effect
inactiv
viru
judg
visual
intact
live
cell
stain
blue
cell
cpe
could
stain
quantiti
protein
inactiv
viru
determin
nm
spectrophotometri
eighti
microgram
inactiv
viru
use
per
mous
subcutan
sc
immun
alum
adjuv
intranas
immun
g
inactiv
virus
l
phosphat
buffer
salin
pb
use
per
mous
without
adjuv
adjuv
use
immun
either
phosphorothiatemodifi
cpg
oligonucleotid
tccatgacgttctgagcttcctgatgct
synthes
purifi
sb
gentech
co
ltd
shanghai
china
gmous
cholera
toxin
b
ctb
sigma
gmous
polyethylen
glycol
peg
mw
use
precipit
inactiv
viru
adjust
g
l
pb
intranas
immun
balbc
mice
g
male
use
experi
mice
underw
light
ether
anesthesia
immun
intranas
l
inactiv
viru
l
inactiv
viru
contain
adjuv
nostril
pegprecipit
inactiv
viru
l
deliv
nostril
group
mice
immun
total
four
time
serum
antisarscov
measur
neutral
test
two
week
last
boost
mice
sacrif
tracheallung
wash
fluid
collect
infus
tracheallung
tract
ml
pb
per
mous
dilut
check
antisarscov
iga
indirect
immunfluorsc
mice
immun
serv
control
noninfect
vero
cell
control
includ
studi
group
mice
immun
differ
adjuv
protocol
immun
list
fig
three
differ
method
use
name
indirect
immunofluores
neutral
test
elisa
indirect
sarscov
infect
cell
fix
slide
mous
sera
tracheallung
wash
fluid
ad
slide
incub
c
min
fitclabel
antimous
igg
iga
use
second
antibodi
convalesc
serum
sar
patient
confirm
neutral
test
use
posit
control
uninfect
cell
nonimmun
mous
serum
tracheallung
wash
fluid
serv
neg
control
serum
sampl
absorb
pack
vero
cell
prior
stain
order
decreas
nonspecif
background
stain
posit
stain
judg
intens
fluoresc
cell
grade
neg
accordingli
microtit
plate
use
neutral
assay
serial
dilut
serum
sampl
separ
mix
tcid
viru
incub
h
ad
vero
cell
sera
nonimmun
mice
use
neg
control
assay
viru
backtitr
viru
serial
dilut
medium
viru
posit
control
tcid
neg
cell
control
medium
parallel
neutral
test
includ
dilut
serum
viru
control
test
quadrupl
result
observ
daili
cpe
endpoint
read
record
day
viru
inocul
tcid
calcul
reedmuench
method
titer
neutral
antibodi
determin
base
highest
dilut
serum
complet
suppress
cpe
induc
viru
least
elisa
commerci
avail
elisa
kit
manufactur
huada
co
beij
china
use
antigen
use
kit
crude
lysat
sarscov
infect
vero
cell
label
antimous
ig
use
second
antibodi
assay
procedur
carri
accord
direct
recommend
manufactur
block
effect
inactiv
virus
versu
live
viru
replic
shown
tabl
compar
control
live
viru
infect
cell
inactiv
viru
di
cytopath
effect
observ
cytopath
effect
detect
lution
tcid
treat
cell
result
time
fall
tcid
contrast
inactiv
influenza
type
viru
show
block
effect
replic
live
viru
cell
tcid
influenza
type
viru
treat
vero
cell
control
nontreat
cell
formaldehyd
dilut
accord
prepar
inactiv
viru
mocktreat
cell
block
effect
live
viru
replic
observ
two
subcutan
inject
g
inactiv
viru
low
titer
elisa
antibodi
detect
three
five
mice
sc
group
sera
group
neg
howev
sera
sc
group
assay
neutral
test
nt
show
posit
result
sinc
nt
sensit
elisa
sera
group
mice
fourth
immuniza
compar
one
nt
assay
result
shown
fig
sc
mice
develop
high
titer
neutral
antibodi
highest
four
dose
immun
inactiv
viru
without
adjuv
substanti
level
serum
neutral
antibodi
detect
mice
due
viscos
peg
precipit
inactiv
sarscov
although
lower
dosag
viru
use
immun
serum
neutral
antibodi
titer
mice
group
tracheallungwash
fluid
test
antisar
iga
posit
stain
detect
group
immun
inactiv
viru
howev
strong
stain
dilut
shown
group
mice
immun
viru
plu
adjuv
mice
immun
peginactiv
viru
fig
date
sever
approach
develop
sar
vaccin
describ
includ
subcutan
immun
inactiv
vaccin
express
recombin
spike
protein
adenoviru
use
synthet
oligonucleotid
code
spike
protein
produc
recombin
immunogen
studi
formaldehyd
inactiv
sarscov
use
immun
mice
intranas
though
inactiv
viru
partial
purifi
experiment
immun
mice
yield
interest
result
sinc
sarscov
newli
describ
viru
intranas
deliveri
inactiv
viru
explor
aim
studi
investig
whether
approach
immunizatioin
could
induc
serum
antibodi
local
antibodi
ensur
enough
stimulu
given
mice
four
dose
immun
use
prior
sacrif
fig
immunofluoresc
studi
antisarscov
iga
tracheallung
wash
fluid
differ
group
intranas
immun
mice
sarscov
infect
cell
noninfect
control
cell
stain
separ
tracheallung
wash
fluid
differ
group
immun
mice
fitclabel
antimous
iga
use
second
antibodi
immunofluoresc
observ
grade
state
tabl
ing
anim
studi
antibodi
tracheallung
wash
fluid
intranas
immun
inactiv
virus
succeed
induc
effect
antibodi
studi
sever
approach
increas
efficaci
intranas
mucos
immun
inactiv
virus
inactiv
bacteria
construct
contain
viral
bacteri
protein
present
studi
use
cpgodn
ctb
adjuv
pegprecipit
inactiv
viru
use
potenti
uptak
inactiv
virus
antigen
present
cell
maintain
inactiv
virus
site
administr
four
intranas
dose
inactiv
viru
serum
antisarscov
neutral
antibodi
detect
antisarsiga
found
tracheallung
wash
fluid
contrast
inactiv
viru
coadminist
intranas
adjuv
either
cpg
ctb
serum
antisarscov
neutral
antibodi
specif
iga
tracheallung
wash
fluid
detect
tabl
fig
result
indic
local
iga
antibodi
could
induc
combin
inactiv
viru
adjuv
hand
mice
immun
subcutan
inactiv
viru
asid
high
titer
serum
neutral
antibodi
specif
antisarsigg
also
could
detect
tracheallung
wash
fluid
howev
antisarsiga
detect
indic
antibodi
detect
tracheal
lung
fluid
produc
local
deriv
serum
antibodi
given
ctb
report
less
toxic
host
modifi
ctb
shown
nontox
human
could
expect
approv
human
use
futur
cpgodn
nontox
induc
effect
humor
cellular
immun
respons
host
thu
promis
adjuv
use
sarscov
intranas
immun
previou
report
use
cpgodn
hbsaganihb
complex
intranas
immun
mice
suggest
select
stimul
humor
respons
cellular
respons
depend
differ
construct
antigen
futur
studi
use
construct
inactiv
sarscov
cpg
odn
intranas
deliveri
might
induc
cell
mediat
immun
immun
respons
antibodi
respons
due
lack
avail
peptid
antigen
studi
sarscov
ctl
cell
prolifer
respons
cellular
immun
respons
sarsvcov
intranas
immun
mice
studi
cellmedi
immun
respons
humor
immun
respons
import
sar
protect
studi
done
whenev
product
inactiv
viru
approv
peg
use
purif
inactiv
hav
vaccin
peginterferon
alreadi
use
clinic
trial
treatment
viral
hepat
b
c
far
seriou
ill
effect
describ
therefor
use
peg
precipit
sarscov
inactiv
viru
intranas
immun
mice
number
anim
use
intranas
immun
group
limit
statist
differ
could
drawn
group
howev
compar
dosag
use
cpg
adjuv
half
dosag
inactiv
viru
necessari
induc
local
serum
specif
antibodi
use
peg
precipit
adjuv
precipit
inactiv
viru
therefor
also
good
candid
develop
intranas
sarscov
inactiv
vaccin
prior
use
formaldehyd
inactiv
immun
test
whether
formaldehydeinactiv
viru
retain
properti
bind
cell
receptor
vitro
result
block
assay
confirm
inactiv
viru
could
block
replic
live
viru
cell
strain
live
viru
avail
could
studi
whether
inactiv
could
block
sarscov
strain
recent
angiotensinconvert
enzym
report
function
receptor
sarscov
whether
success
block
inactiv
versu
live
associ
receptor
remain
studi
besdi
present
block
effect
shown
cell
cultur
would
interest
block
experi
anim
model
similar
result
obtain
inactiv
viru
could
use
intranas
urgent
prevent
measur
outbreak
occur
though
due
technic
problem
neutral
function
iga
tracheallung
wash
fluid
confirm
success
induct
iga
antibodi
sarscov
intranas
immun
suggest
sarscov
could
block
site
entri
would
protect
vaccin
recipi
sarscov
infect
even
viru
broke
frontlin
serumneutr
antibodi
could
interact
neutral
viru
presumpt
howev
valid
anim
model
mimick
sar
